POINT RICHMOND, Calif., Feb. 28, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present a general corporate overview at the 33 rd Annual Cowen and Company Health Care Conference on March 6, 2013, at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available in the investor relations section of the Transcept website at www.transcept.com, and a replay will be available there for approximately 30 days following the event. About Transcept Pharmaceuticals Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.MyIntermezzo.com. Contact: Transcept Pharmaceuticals, Inc. Leone Patterson Vice President, Chief Financial Officer (510) 215-3500 email@example.com SOURCE Transcept Pharmaceuticals, Inc.